Organs on Demand
We’re developing personalized, bioengineered organs, in order to solve the global shortage of organs available for transplantation, as well as substantially reduce the need for immunosuppressive drugs following organ transplantation.
Pipeline
Nayacure is building a pipeline of therapeutic assets and product candidates to address a range of diseases.
%402x.png)
ARTIFICIAL CLOT FOR LOCALIZED DRUG DELIVERY
We’re developing a better way to deliver drugs to specific sites of disease.
Our technology is based on the natural ability of drugs to bind to plasma proteins.
ORGANS ON DEMAND
We’re taking an engineering approach to immune tolerance.
Our goal is to generate an unlimited supply of humanized organs, to address the global shortage of organs available for transplantation.
PLACENTAL STEM CELL DERIVED THERAPY FOR NEURODEGENERATION
The therapeutic effect of stem cells is mediated by molecules they produce.
We're harnessing these molecules produced by the cells and use them for therapy instead of using the cells themselves, thus solving many cell-related problems.
Approach
We seek innovative ideas to solve complex problems.
Simplicity and creativity are at the heart of our innovation.
Shahar Cohen, MD
Founder
About us
Nayacure Labs is an early-stage regenerative medicine company whose mission is to discover and develop technologies to restore the function of failing body parts and extend human life.
The company was founded by Dr. Shahar Cohen, MD, a physician, researcher and entrepreneur. Formerly a research fellow at Tissue Engineering Centre, Imperial College London (UK) and at Stem Cell Center, Faculty of Medicine, Technion (Israel), Dr. Cohen has published several peer reviewed scientific papers, including cover art in Tissue Engineering, book chapter, Acta Biomaterialia paper, Artificial Organs paper, nature's Scientific Reports paper, abstracts in Conference Proceedings, and has several issued or pending patents.